BEST-CLI Landmark Trial Published in NEJM

BEST-CLI is an international research study aimed at figuring out the best treatment for people with peripheral arterial disease (PAD) - also known as poor blood flow, and associated with Critical Limb Ischemia (CLI). It is Federally funded by the National Heart, Lung and Blood Institute at the National Institutes of Health. 

As of November 2022, BEST-CLI enrollment ended in October of 2019, and completed a minimum of 24 months' follow-up for all patients in October of 2021. The primary clinical and quality of life results were presented at the American Heart Association in Chicago, Illinois on Monday, November 7, 2022. The results were published in the New England Journal of Medicine.

NEJM tweeted, "In a randomized trial of patients with limb ischemia, those assigned to bypass surgery as compared with endovascular therapy as an initial strategy had fewer adverse limb events or all-cause death at a median of 2.7 years."

Congratulations to the BEST-CLI team including our very own Drs. Conte, Gasper, and Schneider, and all of the co-authors involved on this landmark trial!